These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 21386092

  • 1. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ.
    Circ Cardiovasc Interv; 2011 Apr 01; 4(2):180-7. PubMed ID: 21386092
    [Abstract] [Full Text] [Related]

  • 2. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
    Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P.
    Thromb Haemost; 2011 Sep 01; 106(3):491-9. PubMed ID: 21800009
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.
    Circulation; 2007 Jun 26; 115(25):3156-64. PubMed ID: 17562955
    [Abstract] [Full Text] [Related]

  • 4. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
    DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA.
    Diabetes; 2007 Dec 26; 56(12):3014-9. PubMed ID: 17848625
    [Abstract] [Full Text] [Related]

  • 5. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P.
    Am Heart J; 2012 Oct 26; 164(4):600-606.e1. PubMed ID: 23067920
    [Abstract] [Full Text] [Related]

  • 6. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A.
    J Am Coll Cardiol; 2010 Mar 16; 55(11):1139-46. PubMed ID: 20223369
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA.
    Circulation; 2007 Feb 13; 115(6):708-16. PubMed ID: 17261652
    [Abstract] [Full Text] [Related]

  • 8. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA, Ozdemir K, Aygul N, Soylu A, Tokac M.
    Am J Cardiol; 2008 Aug 15; 102(4):396-400. PubMed ID: 18678294
    [Abstract] [Full Text] [Related]

  • 9. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS, Hvas AM, Grove EL, Refsgaard J, Rocca B, Daví G, Kristensen SD.
    Thromb Res; 2009 May 15; 124(1):96-100. PubMed ID: 19215971
    [Abstract] [Full Text] [Related]

  • 10. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C.
    J Am Coll Cardiol; 2009 Feb 24; 53(8):667-77. PubMed ID: 19232899
    [Abstract] [Full Text] [Related]

  • 11. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L, Rosiak M, Golanski J, Rysz J, Spychalska M, Watala C.
    Basic Clin Pharmacol Toxicol; 2006 May 24; 98(5):503-9. PubMed ID: 16635110
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, Duarte VE, Cho JR, Been L, Zenni MM, Bass TA, Angiolillo DJ.
    Circulation; 2016 Sep 13; 134(11):780-92. PubMed ID: 27559041
    [Abstract] [Full Text] [Related]

  • 13. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.
    Bliden KP, Tantry US, DiChiara J, Gurbel PA.
    Circ Cardiovasc Interv; 2011 Apr 01; 4(2):118-20. PubMed ID: 21505165
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
    Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA.
    J Clin Pharm Ther; 2012 Dec 01; 37(6):630-6. PubMed ID: 23121257
    [Abstract] [Full Text] [Related]

  • 17. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
    Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P.
    Clin Pharmacol Ther; 2006 Sep 01; 80(3):264-74. PubMed ID: 16952493
    [Abstract] [Full Text] [Related]

  • 18. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P.
    Thromb Haemost; 2006 Apr 01; 95(4):652-8. PubMed ID: 16601836
    [Abstract] [Full Text] [Related]

  • 19. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH, Grove EL, Würtz M, Kristensen SD, Hvas AM.
    Platelets; 2015 Apr 01; 26(3):230-5. PubMed ID: 24750015
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.